SCHEMBL13334538

SCHEMBL13334538

C#C[C@H]1[C@H]2C[C@H]2C2[C@@H]3C(C)CC4=CC(=O)CC[C@@H]4C3CC[C@@]21C

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ AR P10275 9/20 0.56
▸ PGR P06401 9/20 0.52
▸ NR3C2 P08235 2/20 0.46
▸ SHBG P04278 3/20 0.43
▸ ALDH1A1 P00352 2/20 0.41
▸ SERPINA6 P08185 2/20 0.41
▸ SLC22A1 O15245 1/20 0.41
▸ THRB P10828 1/20 0.41
▸ LMNA P02545 2/20 0.40
▸ CYP3A4 P08684 2/20 0.40
▸ ABCB11 O95342 2/20 0.40
▸ TSHR P16473 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ HIF1A Q16665 1/20 0.40
▸ ESR1 P03372 1/20 0.40
▸ NR3C1 P04150 1/20 0.40
▸ ADRA2A P08913 1/20 0.40
▸ SLC6A4 P31645 1/20 0.40
▸ CYP19A1 P11511 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10089119 0.89 AR (0.56) ARPGRNR3C2SHBGALDH1A1
SCHEMBL10089123 0.89 AR (0.56) ARPGRNR3C2SHBGALDH1A1
SCHEMBL4207073 0.89 AR (0.56) ARPGRNR3C2SHBGALDH1A1
SCHEMBL4207041 0.89 AR (0.56) ARPGRNR3C2SHBGALDH1A1
SCHEMBL14010737 0.88 AR (0.52) ARPGRNR3C2SHBGALDH1A1
SCHEMBL13334842 0.87 PGR (0.54) ARPGRNR3C2SHBGALDH1A1
SCHEMBL14009966 0.86 AR (0.54) ARPGRNR3C2SHBGALDH1A1
SCHEMBL13474771 0.84 SHBG (0.54) ARPGRSHBGALDH1A1SERPINA6
SCHEMBL13334450 0.82 AR (0.51) ARPGRSHBGALDH1A1SERPINA6
SCHEMBL13334576 0.82 AR (0.51) ARPGRSHBGALDH1A1SERPINA6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010066355-A1 USE OF 17β-CYANO-19-NOR-ANDROST-4-ENE DERIVATIVES FOR MANUFACTURING A MEDICAMENT IN A SUSTAINED-RELEASE FORM FOR PARENTERAL USE, AND SUSTAINED-RELEASE MEDICAMENT CONTAINING 17β-CYANO-19-NOR-ANDROST-4-ENE DERIVATIVES FOR PARENTERAL USE BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-06-17 — — WO disclosed
Send feedback